中南米のバイオ医薬品市場2028年予測：地域別分析：製品タイプ別、用途別

中南米のバイオ医薬品市場は2022年に178億5,000万米ドルとなり、2028年には349億7,000万米ドルに達すると予測されています。2022年から2028年までのCAGRは11.9%と推定されます。

バイオ医薬品の受託製造が中南米のバイオ医薬品市場を牽引

医薬品製造受託機関（CMO）は製薬企業に多くのメリットをもたらします。CMOに業務を委託することで、製造施設の運営・維持に必要な投資が削減され、純キャッシュフローの改善につながります。アウトソーシングはコストが安く、製造プロセスの効率を高める。また、バイオ医薬品企業はリソースを他の重要な分野に振り向けることができます。多くのバイオ製薬企業は、研究開発などの中核能力に再注力しており、その結果、自社製造能力の売却が進み、製造におけるCMOへの依存度が高まっています。CMOは、製薬会社が供給不足のリスクを軽減するために、多拠点供給戦略やバックアップ能力を通じて、追加能力を提供し、追加拠点を提供します。例えば、2022年3月、バイオエヌテックSEは、進行非小細胞肺がん（NSCLC）治療のためのPD-1阻害剤であるLibtayo（cemiplimab）と併用するFixVac候補BNT116を前進させるためのリジェネロンとの提携を発表しました。この提携契約により、両社は進行NSCLCを患う様々な患者を対象に、併用療法を評価する臨床試験を共同で実施することになります。このように、バイオ医薬品の受託製造の人気の高まりは、今後数年間の中南米バイオ医薬品市場の成長を促進すると思われます。

中南米バイオ医薬品市場概要

中南米バイオ医薬品市場は、ブラジル、アルゼンチン、その他の中南米に区分されます。中南米のイメージングセンターではデジタルX線撮影が普及しています。南米・中米におけるバイオ医薬品市場の成長要因としては、がん罹患率の高さ、バイオ医薬品技術の革新の進展、がん罹患リスクの高い老年人口の増加、今後開発される様々な新薬の調査研究などが挙げられます。バイオ医薬品は、医学史上最も重要な技術革新のひとつです。しかし、こうした画期的な治療法は、その発見と開発に多額の投資が必要なため非常に高価であり、より安価な代替品が求められています。中南米は、生物学的製剤、特にバイオシミラーにとって大きなチャンスです。中南米では、バイオシミラーに関する知識や開発レベルが高いため、国内外の製薬会社がこの市場に参入し、国内外で研究、製造、商業化を行うことに大きな関心が寄せられています。生物製剤市場は、主に新規分子の発見により、予測期間中に急成長するとみられています。生物製剤の製造に必要な高度な技術と資源は、小規模なバイオテクノロジー企業にとって高い参入障壁となっています。このため、この地域では大手多国籍企業が生物製剤市場全体を支配しています。これらの企業は、常に革新的な新製品を提供することで、バイオシミラー市場で優位に立つために研究開発に多額の投資を行っています。中南米バイオシミラー市場参入企業が直面する主な課題は、研究開発コストの高さ、製品の有効性と安全性を証明するために必要な臨床試験、低価格を維持する必要性などです。中南米では、インスリン、顆粒球コロニー刺激因子（G-CSF）、エリスロポエチン、ヒト成長ホルモンのバイオシミラー製品が最初に市場に登場しました。その後、インターフェロンが登場し、最後にモノクローナル抗体が登場しました。さらに、リツキシマブ、エタネルセップ、ラコツヌマブなどの製品が中南米に市場参入すれば、バイオシミラー市場が拡大すると思われます。地理的な拡大と経済成長を背景に、複数の世界製薬企業がブラジル市場を選択しています。彼らはバイオシミラー市場に長けているため、地元企業のみで迅速な市場拡大に貢献し、同地域の中南米バイオ医薬品市場を押し上げると思われます。

中南米バイオ医薬品市場の収益と2028年までの予測（10億米ドル）

中南米バイオ医薬品市場のセグメンテーション

中南米のバイオ医薬品市場は、製品タイプ、用途、国に区分されます。

製品タイプ別に見ると、中南米のバイオ医薬品市場は、モノクローナル抗体、組み換えワクチン、従来型ワクチン、組み換え成長因子、精製タンパク質、組み換えタンパク質、組み換えホルモン、組み換え酵素、細胞・遺伝子治療、サイトカイン・インターフェロン・インターロイキン、その他に区分されます。2022年には、モノクローナル抗体分野が中南米バイオ医薬品市場で最大のシェアを占めました。

組み換えワクチン分野はさらに、がんワクチン、マラリアワクチン、エボラワクチン、B型肝炎ワクチン、破傷風ワクチン、ジフテリアワクチン、コレラワクチン、その他に区分されます。従来型ワクチン分野は、さらにポリオワクチン、ポックスワクチン、その他に細分化されます。組換え成長因子セグメントはさらにエリスロポエチン、顆粒球コロニー刺激因子にセグメント化されます。精製タンパク質セグメントはさらに白血病抑制因子（LIF）、P53タンパク質、P38タンパク質、その他に細分化されます。組換えタンパク質セグメントは、さらに血清アルブミン、アミロイドタンパク質、ディフェンシン、トランスフェリンにセグメント化されます。遺伝子組換えホルモンは、さらに遺伝子組換えヒト成長ホルモン、遺伝子組換えインスリン、その他の遺伝子組換えホルモンに区分されます。組換え酵素セグメントはさらに、エンテロキナーゼ、シクラーゼ、カスパーゼ、カテプシンに区分されます。細胞・遺伝子治療分野はさらに、同種製品、自家製品、無細胞製品に区分されます。

用途別では、中南米のバイオ医薬品市場は、がん、炎症・感染症、自己免疫疾患、代謝疾患、ホルモン疾患・成長不全、心血管疾患、神経疾患、その他に区分されます。2022年、中南米のバイオ医薬品市場では、がん領域が最大のシェアを占めました。

国別に見ると、中南米のバイオ医薬品市場はブラジル、アルゼンチン、その他の南米に区分されます。2022年には、ブラジルが中南米バイオ医薬品市場で最大のシェアを占めました。

AbbVie Inc、AGC Biologics AS、Amgen Inc、Boehringer Ingelheim International GmbH、Bristol-Myers Squibb Co、Eli Lilly and Co、Johnson &Johnson、Lonza Group AG、Thermo Fisher Scientific Incなどが中南米バイオ医薬品市場で事業を展開する大手企業です。

目次

第1章 イントロダクション

第2章 中南米バイオ医薬品市場-要点

第3章 調査手法

• 調査範囲
• 2次調査
• 1次調査

第4章 中南米のバイオ医薬品市場：市場情勢

• 概要
• 中南米のPEST分析
• 専門家の見解

第5章 南米・中南米バイオ医薬品市場：主要市場力学

• 市場促進要因
  • がん治療薬への応用拡大
  • 希少疾患治療の可能性
• 市場抑制要因
  • 製造インフラの高コスト
• 市場機会
  • 臨床試験の加速
• 今後の動向
  • バイオ医薬品の受託製造
• 影響分析

第6章 バイオ医薬品市場：中南米分析

• 中南米バイオ医薬品市場の収益予測と分析

第7章 中南米バイオ医薬品市場- 製品タイプ別収益と2028年までの予測

• 概要
• バイオ医薬品市場の製品タイプ別収益シェア（2021年・2028年）
• モノクローナル抗体
• 組み換えワクチン
• 従来型ワクチン
• 組み換え成長因子
• 精製タンパク質
• 組み換えタンパク質
• 組み換えホルモン
• 組み換え酵素
• 細胞および遺伝子治療
• サイトカイン/インターフェロン/インターロイキン
• その他（mRNAベース治療薬など）

第8章 中南米バイオ医薬品市場の分析と2028年までの予測：用途別

• 概要
• 中南米のバイオ医薬品市場：用途別、2021年・2028年（%）
• がん領域
• 炎症性疾患および感染性疾患
• 自己免疫疾患
• 代謝疾患
• ホルモン障害と成長不全
• 心血管疾患
• 神経疾患
• その他の治療用途

第9章 中南米バイオ医薬品市場：収益と2028年までの予測：国別分析

• 中南米
  • ブラジル
  • アルゼンチン
  • その他の中南米

第10章 中南米バイオ医薬品市場：業界情勢

• 有機的成長戦略
• 無機的成長戦略

第11章 企業プロファイル

• Amgen Inc
• AbbVie Inc
• Eli Lilly and Co
• Bristol-Myers Squibb Co
• Johnson & Johnson
• Boehringer Ingelheim International GmbH
• Thermo Fisher Scientific Inc
• AGC Biologics AS
• Lonza Group AG

第12章 付録

List Of Tables

• Table 1. South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• Table 2. Brazil Biopharmaceuticals Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
• Table 3. Brazil Biopharmaceuticals Market, by Recombinant Vaccines - Revenue and Forecast to 2028 (US$ Million)
• Table 4. Brazil Biopharmaceuticals Market, by Conventional Vaccines - Revenue and Forecast to 2028 (US$ Million)
• Table 5. Brazil Biopharmaceuticals Market, by Recombinant Growth Factors - Revenue and Forecast to 2028 (US$ Million)
• Table 6. Brazil Biopharmaceuticals Market, by Purified Proteins - Revenue and Forecast to 2028 (US$ Million)
• Table 7. Brazil Biopharmaceuticals Market, by Recombinant Proteins - Revenue and Forecast to 2028 (US$ Million)
• Table 8. Brazil Biopharmaceuticals Market, by Recombinant Hormones - Revenue and Forecast to 2028 (US$ Million)
• Table 9. Brazil Biopharmaceuticals Market, by Recombinant Enzymes - Revenue and Forecast to 2028 (US$ Million)
• Table 10. Brazil Biopharmaceuticals Market, by Cell & Gene Therapies - Revenue and Forecast to 2028 (US$ Million)
• Table 11. Brazil Biopharmaceuticals Market, by Application - Revenue and Forecast to 2028 (US$ Million)
• Table 12. Argentina Biopharmaceuticals Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
• Table 13. Argentina Biopharmaceuticals Market, by Recombinant Vaccines - Revenue and Forecast to 2028 (US$ Million)
• Table 14. Argentina Biopharmaceuticals Market, by Conventional Vaccines - Revenue and Forecast to 2028 (US$ Million)
• Table 15. Argentina Biopharmaceuticals Market, by Recombinant Growth Factors - Revenue and Forecast to 2028 (US$ Million)
• Table 16. Argentina Biopharmaceuticals Market, by Purified Proteins - Revenue and Forecast to 2028 (US$ Million)
• Table 17. Argentina Biopharmaceuticals Market, by Recombinant Proteins - Revenue and Forecast to 2028 (US$ Million)
• Table 18. Argentina Biopharmaceuticals Market, by Recombinant Hormones - Revenue and Forecast to 2028 (US$ Million)
• Table 19. Argentina Biopharmaceuticals Market, by Recombinant Enzymes - Revenue and Forecast to 2028 (US$ Million)
• Table 20. Argentina Biopharmaceuticals Market, by Cell & Gene Therapies - Revenue and Forecast to 2028 (US$ Million)
• Table 21. Argentina Biopharmaceuticals Market, by Application - Revenue and Forecast to 2028 (US$ Million)
• Table 22. Rest of South & Central America Biopharmaceuticals Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
• Table 23. Rest of South & Central America Biopharmaceuticals Market, by Recombinant Vaccines - Revenue and Forecast to 2028 (US$ Million)
• Table 24. Rest of South & Central America Biopharmaceuticals Market, by Conventional Vaccines - Revenue and Forecast to 2028 (US$ Million)
• Table 25. Rest of South & Central America Biopharmaceuticals Market, by Recombinant Growth Factors - Revenue and Forecast to 2028 (US$ Million)
• Table 26. Rest of South & Central America Biopharmaceuticals Market, by Purified Proteins - Revenue and Forecast to 2028 (US$ Million)
• Table 27. Rest of South & Central America Biopharmaceuticals Market, by Recombinant Proteins - Revenue and Forecast to 2028 (US$ Million)
• Table 28. Rest of South & Central America Biopharmaceuticals Market, by Recombinant Hormones - Revenue and Forecast to 2028 (US$ Million)
• Table 29. Rest of South & Central America Biopharmaceuticals Market, by Recombinant Enzymes - Revenue and Forecast to 2028 (US$ Million)
• Table 30. Rest of South & Central America Biopharmaceuticals Market, by Cell & Gene Therapies - Revenue and Forecast to 2028 (US$ Million)
• Table 31. Rest of South & Central America Biopharmaceuticals Market, by Application - Revenue and Forecast to 2028 (US$ Million)
• Table 32. Recent Organic Growth Strategies in Biopharmaceuticals Market
• Table 33. Recent Inorganic Growth Strategies in the South & Central America biopharmaceuticals market
• Table 34. Glossary of Terms

List Of Figures

• Figure 1. South & Central America Biopharmaceuticals Market Segmentation
• Figure 2. South & Central America Biopharmaceuticals Market, by Country
• Figure 3. South & Central America Biopharmaceuticals Market Overview
• Figure 4. Monoclonal Antibodies Segment Held Largest Share of Product Type Segment in South & Central America Biopharmaceuticals Market
• Figure 5. Brazil Expected to Show Remarkable Growth During Forecast Period
• Figure 6. South & Central America: PEST Analysis
• Figure 7. Experts\' Opinion
• Figure 8. South & Central America Biopharmaceuticals Market: Impact Analysis of Drivers and Restraints
• Figure 9. South & Central America Biopharmaceuticals Market - Revenue Forecast and Analysis - 2020-2028
• Figure 10. Biopharmaceuticals Market Revenue Share, by Product Type 2021 & 2028 (%)
• Figure 11. Monoclonal Antibodies: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• Figure 12. Recombinant Vaccines: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• Figure 13. Cancer Vaccine: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• Figure 14. Malaria Vaccine: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• Figure 15. Ebola Vaccine: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• Figure 16. Hepatitis-B Vaccine: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• Figure 17. Tetanus Vaccine: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• Figure 18. Diphtheria Vaccine: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• Figure 19. Cholera Vaccine: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• Figure 20. Others: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• Figure 21. Conventional Vaccines: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• Figure 22. Polio Vaccine: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• Figure 23. Pox Vaccine: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• Figure 24. Other Conventional Vaccine: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• Figure 25. Recombinant Growth Factors: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• Figure 26. Erythropoietin: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• Figure 27. Granulocyte Colony Stimulating Factor: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• Figure 28. Purified Proteins: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• Figure 29. Leukemia Inhibitory Factor (LIF): South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• Figure 30. P53 Protein: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• Figure 31. P38 Protein: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• Figure 32. Other Purified Proteins: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• Figure 33. Recombinant Proteins: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• Figure 34. Serum Albumin: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• Figure 35. Amyloid Protein: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• Figure 36. Defensin: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• Figure 37. Transferrin: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• Figure 38. Recombinant Hormones: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• Figure 39. Recombinant Human Growth Hormones: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• Figure 40. Recombinant Insulin: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• Figure 41. Other Recombinant Hormones: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• Figure 42. Recombinant Enzymes: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• Figure 43. Enterokinase: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• Figure 44. Cyclase: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• Figure 45. Caspase: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• Figure 46. Cathepsin: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• Figure 47. Cell and Gene Therapies: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• Figure 48. Allogenic Products: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• Figure 49. Autologous Products: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• Figure 50. Acellular Products: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• Figure 51. Cytokines/Interferon/Interleukins: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• Figure 52. Others (mRNA Based Therapeutics, etc.): South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• Figure 53. South & Central America Biopharmaceuticals Market, by Application 2021 & 2028 (%)
• Figure 54. Oncology: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• Figure 55. Inflammatory and Infectious Diseases: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• Figure 56. Autoimmune Disorders: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• Figure 57. Metabolic Disorders: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• Figure 58. Hormonal Disorders and Growth Failure: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• Figure 59. Cardiovascular Diseases: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• Figure 60. Neurological Diseases: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• Figure 61. Other Therapeutic Applications: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• Figure 62. South & Central America: Biopharmaceuticals Market, by Key Country - Revenue (2021) (US$ Million)
• Figure 63. South & Central America: Biopharmaceuticals Market, by Country, 2021 & 2028 (%)
• Figure 64. Brazil: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• Figure 65. Argentina: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• Figure 66. Rest of South & Central America: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)

The South & Central America biopharmaceuticals market was valued at US$ 17.85 billion in 2022 and is projected to reach US$ 34.97 billion by 2028. It is estimated to grow at a CAGR of 11.9% from 2022 to 2028.

Contract Manufacturing of Biopharmaceuticals Drives South & Central America Biopharmaceuticals Market

Contract manufacturing organizations (CMOs) bring many benefits to the table for pharmaceutical companies. Outsourcing tasks to CMOs help them reduce investments required for operating and maintaining manufacturing facilities, thereby aiding improvements in the net cash flow. Outsourcing is cheaper and increases the efficiency of manufacturing processes. Also, it allows biopharmaceutical companies to redirect resources to other important areas. Many biopharmaceutical companies are refocusing on their core capabilities, such as research and development, leading to divestments of in-house manufacturing capacities, which subsequently results in an increased dependence on CMOs for manufacturing. CMOs provide additional capacities and offer additional sites for pharmaceutical companies to mitigate the risk of supply shortages through multisite supply strategies and backup capacities. For instance, in March 2022, BioNTech SE announced a collaboration with Regeneron to advance the FixVac candidate BNT116 in combination with Libtayo (cemiplimab), a PD-1 inhibitor for treating advanced non-small cell lung cancer (NSCLC). The collaboration agreement allows the companies to jointly conduct clinical trials to evaluate the combination therapy in different patients suffering from advanced NSCLC. Thus, the increasing popularity of biopharmaceuticals contract manufacturing is likely to catalyze the growth of the South & Central America biopharmaceuticals market in the coming years.

South & Central America Biopharmaceuticals Market Overview

The South & Central America Biopharmaceuticals market is segmented into Brazil, Argentina, and the Rest of South & Central America. Digital radiography is becoming more prevalent in imaging centers across South & Central America. The high burden of cancer, ongoing innovations in biopharmaceuticals technologies, increase in the geriatric population that is at a greater risk of cancer, and research studies on various new upcoming medicines are among the factors contributing to the growth of biopharmaceuticals market in South & Central America. Biopharmaceuticals products are among the most important innovations in medical history. However, these breakthrough therapies, which are extremely expensive due to the large investments required for their discovery and development, call for cheaper alternatives. South & Central America provides a great opportunity for biologic medicines, particularly biosimilars. In South & Central America, there is a high level of knowledge and development of biosimilars; hence, there is a great interest in local and foreign pharmaceutical companies to enter the market to research, manufacture, and commercialize locally and internationally. The biologics market is set to grow rapidly over the forecast period, mainly due to the discovery of new molecules. The advanced technology and resources required to manufacture biologics create high barriers to entry for small biotech companies. This explains why large multinational companies dominate the entire biologics market in the region. These companies invest heavily in R&D to stay ahead in the biosimilar market by constantly offering new innovative products. The main challenges faced by participants in the South & Central America biosimilar market are related to the high cost of research and development, the clinical trials required to prove product efficacy and safety, and the need to maintain low-end prices. In South & Central America, the first biosimilar product to appear on the market was insulin: granulocyte colony-stimulating factor (G-CSF), erythropoietin, and human growth hormone. Interferon later came to the region, and finally, monoclonal antibodies. In addition, the market entry of products such as rituximab, etanercep, and racotunumab in South & Central America would expand the market for biosimilars. Several global pharmaceutical companies have chosen the Brazil market due to their geographic expansion and growing economy. Because of their skills in the biosimilars market, they will help expand the market faster with only local companies, thereby boosting the South & Central America biopharmaceuticals market in the region.

South & Central America Biopharmaceuticals Market Revenue and Forecast to 2028 (US$ Billion)

South & Central America biopharmaceuticals market Segmentation

The South & Central America biopharmaceuticals market is segmented into product type, application, and country.

Based on product type, the South & Central America biopharmaceuticals market is segmented into monoclonal antibodies, recombinant vaccines, conventional vaccines, recombinant growth factors, purified proteins, recombinant proteins, recombinant hormones, recombinant enzymes, cell & gene therapies, cytokines/interferon/interleukins, and others. In 2022, the monoclonal antibodies segment held the largest share of the South & Central America biopharmaceuticals market.

The recombinant vaccines segment is further segmented into cancer vaccine, malaria vaccine, Ebola vaccine, hepatitis-B vaccine, tetanus vaccine, diphtheria vaccine, cholera vaccine, and others. The conventional vaccines segment is further segmented into polio vaccine, pox vaccine, and others. The recombinant growth factors segment is further segmented into erythropoietin and granulocyte colony stimulating factor. The purified proteins segment is further segmented into leukemia inhibitory factor (LIF), P53 protein, P38 protein, and others. The recombinant proteins segment is further segmented into serum albumin, amyloid protein, defensin, and transferrin. The recombinant hormones segment is further segmented into recombinant human growth hormones, recombinant insulin, and other recombinant hormones. The recombinant enzymes segment is further segmented into enterokinase, cyclase, caspase, and cathepsin. The cell & gene therapies segment is further segmented into allogenic products, autologous products, and acellular products.

Based on application, the South & Central America biopharmaceuticals market is segmented into oncology, inflammatory & infectious disease, autoimmune disorders, metabolic disorders, hormonal disorders & growth failure, cardiovascular diseases, neurological diseases, and others. In 2022, the oncology segment held the largest share of the South & Central America biopharmaceuticals market.

Based on country, the South & Central America biopharmaceuticals market is segmented into Brazil, Argentina, and the Rest of South & Central America. In 2022, Brazil held the largest share of the South & Central America biopharmaceuticals market.

AbbVie Inc, AGC Biologics AS, Amgen Inc, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Co, Eli Lilly and Co, Johnson & Johnson, Lonza Group AG, and Thermo Fisher Scientific Inc are among the leading companies operating in the South & Central America biopharmaceuticals market.

Reasons to Buy:

• Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the South & Central America biopharmaceutical market.
• Highlights key business priorities in order to assist companies to realign their business strategies
• The key findings and recommendations highlight crucial progressive industry trends in the South & Central America biopharmaceutical market, thereby allowing players across the value chain to develop effective long-term strategies
• develop/modify business expansion plans by using substantial growth offering developed and emerging markets
• Scrutinize in-depth South & Central America market trends and outlook coupled with the factors driving the biopharmaceutical market, as well as those hindering it
• Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution

Table Of Contents

1. Introduction

• 1.1 Scope of the Study
• 1.2 The Insight Partners Research Report Guidance
• 1.3 Market Segmentation
  • 1.3.1 South & Central America Biopharmaceuticals Market - by Product Type
  • 1.3.2 South & Central America Biopharmaceuticals Market - by Application
  • 1.3.3 South & Central America Biopharmaceuticals Market - by Country

2. South & Central America Biopharmaceuticals Market - Key Takeaways

3. Research Methodology

• 3.1 Coverage
• 3.2 Secondary Research
• 3.3 Primary Research

4. South & Central America Biopharmaceuticals Market - Market Landscape

• 4.1 Overview
• 4.2 South & Central America PEST Analysis
• 4.3 Expert's Opinion

5. South & Central America Biopharmaceuticals Market - Key Market Dynamics

• 5.1 Market Drivers
  • 5.1.1 Rising Application in Cancer Therapeutics
  • 5.1.2 Potential to Treat Rare Diseases
• 5.2 Market Restraints
  • 5.2.1 High Cost of Manufacturing Infrastructure
• 5.3 Market Opportunities
  • 5.3.1 Accelerated Clinical Trials
• 5.4 Future Trends
  • 5.4.1 Contract Manufacturing of Biopharmaceuticals
• 5.5 Impact Analysis

6. Biopharmaceuticals Market - South & Central America Analysis

• 6.1 South & Central America Biopharmaceuticals Market Revenue Forecast and Analysis

7. South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 - by Product Type

• 7.1 Overview
• 7.2 Biopharmaceuticals Market Revenue Share, by Product Type 2021 & 2028 (%)
• 7.3 Monoclonal Antibodies
  • 7.3.1 Overview
  • 7.3.2 Monoclonal Antibodies: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• 7.4 Recombinant Vaccines
  • 7.4.1 Overview
  • 7.4.2 Recombinant Vaccines: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
    • 7.4.2.1 Cancer Vaccine
      • 7.4.2.1.1 Overview
      • 7.4.2.1.2 Cancer Vaccine: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
    • 7.4.2.2 Malaria Vaccine
      • 7.4.2.2.1 Overview
      • 7.4.2.2.2 Malaria Vaccine: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
    • 7.4.2.3 Ebola Vaccine
      • 7.4.2.3.1 Overview
      • 7.4.2.3.2 Ebola Vaccine: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
    • 7.4.2.4 Hepatitis-B Vaccine
      • 7.4.2.4.1 Overview
      • 7.4.2.4.2 Hepatitis-B Vaccine: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
    • 7.4.2.5 Tetanus Vaccine
      • 7.4.2.5.1 Overview
      • 7.4.2.5.2 Tetanus Vaccine: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
    • 7.4.2.6 Diphtheria Vaccine
      • 7.4.2.6.1 Overview
      • 7.4.2.6.2 Diphtheria Vaccine: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
    • 7.4.2.7 Cholera Vaccine
      • 7.4.2.7.1 Overview
      • 7.4.2.7.2 Cholera Vaccine: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
    • 7.4.2.8 Others
      • 7.4.2.8.1 Overview
      • 7.4.2.8.2 Others: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• 7.5 Conventional Vaccines
  • 7.5.1 Overview
  • 7.5.2 Conventional Vaccines: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
    • 7.5.2.1 Polio Vaccine
      • 7.5.2.1.1 Overview
      • 7.5.2.1.2 Polio Vaccine: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
    • 7.5.2.2 Pox Vaccine
      • 7.5.2.2.1 Overview
      • 7.5.2.2.2 Pox Vaccine: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
    • 7.5.2.3 Other Conventional Vaccine
      • 7.5.2.3.1 Overview
      • 7.5.2.3.2 Other Conventional Vaccine: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• 7.6 Recombinant Growth Factors
  • 7.6.1 Overview
  • 7.6.2 Recombinant Growth Factors: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
    • 7.6.2.1 Erythropoietin
      • 7.6.2.1.1 Overview
      • 7.6.2.1.2 Erythropoietin: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
    • 7.6.2.2 Granulocyte Colony Stimulating Factor
      • 7.6.2.2.1 Overview
      • 7.6.2.2.2 Granulocyte Colony Stimulating Factor: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• 7.7 Purified Proteins
  • 7.7.1 Overview
  • 7.7.2 Purified Proteins: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
    • 7.7.2.1 Leukemia Inhibitory Factor (LIF)
      • 7.7.2.1.1 Overview
      • 7.7.2.1.2 Leukemia Inhibitory Factor (LIF): South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
    • 7.7.2.2 P53 Protein
      • 7.7.2.2.1 Overview
      • 7.7.2.2.2 P53 Protein: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
    • 7.7.2.3 P38 Protein
      • 7.7.2.3.1 Overview
      • 7.7.2.3.2 P38 Protein: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
    • 7.7.2.4 Other Purified Proteins
      • 7.7.2.4.1 Overview
      • 7.7.2.4.2 Other Purified Proteins: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• 7.8 Recombinant Proteins
  • 7.8.1 Overview
  • 7.8.2 Recombinant Proteins: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
    • 7.8.2.1 Serum Albumin
      • 7.8.2.1.1 Overview
      • 7.8.2.1.2 Serum Albumin: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
    • 7.8.2.2 Amyloid Protein
      • 7.8.2.2.1 Overview
      • 7.8.2.2.2 Amyloid Protein: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
    • 7.8.2.3 Defensin
      • 7.8.2.3.1 Overview
      • 7.8.2.3.2 Defensin: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
    • 7.8.2.4 Transferrin
      • 7.8.2.4.1 Overview
      • 7.8.2.4.2 Transferrin: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• 7.9 Recombinant Hormones
  • 7.9.1 Overview
  • 7.9.2 Recombinant Hormones: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
    • 7.9.2.1 Recombinant Human Growth Hormones
      • 7.9.2.1.1 Overview
      • 7.9.2.1.2 Recombinant Human Growth Hormones: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
    • 7.9.2.2 Recombinant Insulin
      • 7.9.2.2.1 Overview
      • 7.9.2.2.2 Recombinant Insulin: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
    • 7.9.2.3 Other Recombinant Hormones
      • 7.9.2.3.1 Overview
      • 7.9.2.3.2 Other Recombinant Hormones: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• 7.10 Recombinant Enzymes
  • 7.10.1 Overview
  • 7.10.2 Recombinant Enzymes: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
    • 7.10.2.1 Enterokinase
      • 7.10.2.1.1 Overview
      • 7.10.2.1.2 Enterokinase: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
    • 7.10.2.2 Cyclase
      • 7.10.2.2.1 Overview
      • 7.10.2.2.2 Cyclase: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
    • 7.10.2.3 Caspase
      • 7.10.2.3.1 Overview
      • 7.10.2.3.2 Caspase: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
    • 7.10.2.4 Cathepsin
      • 7.10.2.4.1 Overview
      • 7.10.2.4.2 Cathepsin: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• 7.11 Cell and Gene Therapies
  • 7.11.1 Overview
  • 7.11.2 Cell and Gene Therapies: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
    • 7.11.2.1 Allogenic Products
      • 7.11.2.1.1 Overview
      • 7.11.2.1.2 Allogenic Products: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
    • 7.11.2.2 Autologous Products
      • 7.11.2.2.1 Overview
      • 7.11.2.2.2 Autologous Products: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
    • 7.11.2.3 Acellular Products
      • 7.11.2.3.1 Overview
      • 7.11.2.3.2 Acellular Products: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• 7.12 Cytokines/Interferon/Interleukins
  • 7.12.1 Overview
  • 7.12.2 Cytokines/Interferon/Interleukins: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• 7.13 Others (mRNA Based Therapeutics, etc.)
  • 7.13.1 Overview
  • 7.13.2 Others (mRNA Based Therapeutics, etc.): South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)

8. South & Central America Biopharmaceuticals Market Analysis and Forecasts to 2028 - by Application

• 8.1 Overview
• 8.2 South & Central America Biopharmaceuticals Market, by Application 2021 & 2028 (%)
• 8.3 Oncology
  • 8.3.1 Overview
  • 8.3.2 Oncology: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• 8.4 Inflammatory and Infectious Diseases
  • 8.4.1 Overview
  • 8.4.2 Inflammatory and Infectious Diseases: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• 8.5 Autoimmune Disorders
  • 8.5.1 Overview
  • 8.5.2 Autoimmune Disorders: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• 8.6 Metabolic Disorders
  • 8.6.1 Overview
  • 8.6.2 Metabolic Disorders: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• 8.7 Hormonal Disorders and Growth Failure
  • 8.7.1 Overview
  • 8.7.2 Hormonal Disorders and Growth Failure: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• 8.8 Cardiovascular Diseases
  • 8.8.1 Overview
  • 8.8.2 Cardiovascular Diseases: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• 8.9 Neurological Diseases
  • 8.9.1 Overview
  • 8.9.2 Neurological Diseases: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• 8.10 Other Therapeutic Applications
  • 8.10.1 Overview
  • 8.10.2 Other Therapeutic Applications: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)

9. South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 - Country Analysis

• 9.1 Overview
  • 9.1.1 South & Central America: Biopharmaceuticals Market, by Country, 2021 & 2028 (%)
    • 9.1.1.1 Brazil: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 9.1.1.1.1 Brazil: Biopharmaceuticals Market, by Product Type, 2019-2028 (US$ Million)
      • 9.1.1.1.1.1 Brazil: Biopharmaceuticals Market, by Recombinant Vaccines, 2019-2028 (US$ Million)
      • 9.1.1.1.1.2 Brazil: Biopharmaceuticals Market, by Conventional Vaccines, 2019-2028 (US$ Million)
      • 9.1.1.1.1.3 Brazil: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019-2028 (US$ Million)
      • 9.1.1.1.1.4 Brazil: Biopharmaceuticals Market, by Purified Proteins, 2019-2028 (US$ Million)
      • 9.1.1.1.1.5 Brazil: Biopharmaceuticals Market, by Recombinant Proteins, 2019-2028 (US$ Million)
      • 9.1.1.1.1.6 Brazil: Biopharmaceuticals Market, by Recombinant Hormones, 2019-2028 (US$ Million)
      • 9.1.1.1.1.7 Brazil: Biopharmaceuticals Market, by Recombinant Enzymes, 2019-2028 (US$ Million)
      • 9.1.1.1.1.8 Brazil: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019-2028 (US$ Million)
      • 9.1.1.1.2 Brazil: Biopharmaceuticals Market, by Application, 2019-2028 (US$ Million)
    • 9.1.1.2 Argentina: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 9.1.1.2.1 Argentina: Biopharmaceuticals Market, by Product Type, 2019-2028 (US$ Million)
      • 9.1.1.2.1.1 Argentina: Biopharmaceuticals Market, by Recombinant Vaccines, 2019-2028 (US$ Million)
      • 9.1.1.2.1.2 Argentina: Biopharmaceuticals Market, by Conventional Vaccines, 2019-2028 (US$ Million)
      • 9.1.1.2.1.3 Argentina: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019-2028 (US$ Million)
      • 9.1.1.2.1.4 Argentina: Biopharmaceuticals Market, by Purified Proteins, 2019-2028 (US$ Million)
      • 9.1.1.2.1.5 Argentina: Biopharmaceuticals Market, by Recombinant Proteins, 2019-2028 (US$ Million)
      • 9.1.1.2.1.6 Argentina: Biopharmaceuticals Market, by Recombinant Hormones, 2019-2028 (US$ Million)
      • 9.1.1.2.1.7 Argentina: Biopharmaceuticals Market, by Recombinant Enzymes, 2019-2028 (US$ Million)
      • 9.1.1.2.1.8 Argentina: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019-2028 (US$ Million)
      • 9.1.1.2.2 Argentina: Biopharmaceuticals Market, by Application, 2019-2028 (US$ Million)
    • 9.1.1.3 Rest of South & Central America: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 9.1.1.3.1 Rest of South & Central America: Biopharmaceuticals Market, by Product Type, 2019-2028 (US$ Million)
      • 9.1.1.3.1.1 Rest of South & Central America: Biopharmaceuticals Market, by Recombinant Vaccines, 2019-2028 (US$ Million)
      • 9.1.1.3.1.2 Rest of South & Central America: Biopharmaceuticals Market, by Conventional Vaccines, 2019-2028 (US$ Million)
      • 9.1.1.3.1.3 Rest of South & Central America: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019-2028 (US$ Million)
      • 9.1.1.3.1.4 Rest of South & Central America: Biopharmaceuticals Market, by Purified Proteins, 2019-2028 (US$ Million)
      • 9.1.1.3.1.5 Rest of South & Central America: Biopharmaceuticals Market, by Recombinant Proteins, 2019-2028 (US$ Million)
      • 9.1.1.3.1.6 Rest of South & Central America: Biopharmaceuticals Market, by Recombinant Hormones, 2019-2028 (US$ Million)
      • 9.1.1.3.1.7 Rest of South & Central America: Biopharmaceuticals Market, by Recombinant Enzymes, 2019-2028 (US$ Million)
      • 9.1.1.3.1.8 Rest of South & Central America: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019-2028 (US$ Million)
      • 9.1.1.3.2 Rest of South & Central America: Biopharmaceuticals Market, by Application, 2019-2028 (US$ Million)

10. South & Central America Biopharmaceuticals Market - Industry Landscape

• 10.1 Overview
• 10.2 Organic Growth Strategies
  • 10.2.1 Overview
• 10.3 Inorganic Growth Strategies
  • 10.3.1 Overview

11. Company Profiles

• 11.1 Amgen Inc
  • 11.1.1 Key Facts
  • 11.1.2 Business Description
  • 11.1.3 Products and Services
  • 11.1.4 Financial Overview
  • 11.1.5 SWOT Analysis
  • 11.1.6 Key Developments
• 11.2 AbbVie Inc
  • 11.2.1 Key Facts
  • 11.2.2 Business Description
  • 11.2.3 Products and Services
  • 11.2.4 Financial Overview
  • 11.2.5 SWOT Analysis
  • 11.2.6 Key Developments
• 11.3 Eli Lilly and Co
  • 11.3.1 Key Facts
  • 11.3.2 Business Description
  • 11.3.3 Products and Services
  • 11.3.4 Financial Overview
  • 11.3.5 SWOT Analysis
  • 11.3.6 Key Developments
• 11.4 Bristol-Myers Squibb Co
  • 11.4.1 Key Facts
  • 11.4.2 Business Description
  • 11.4.3 Products and Services
  • 11.4.4 Financial Overview
  • 11.4.5 SWOT Analysis
  • 11.4.6 Key Developments
• 11.5 Johnson & Johnson
  • 11.5.1 Key Facts
  • 11.5.2 Business Description
  • 11.5.3 Products and Services
  • 11.5.4 Financial Overview
  • 11.5.5 SWOT Analysis
  • 11.5.6 Key Developments
• 11.6 Boehringer Ingelheim International GmbH
  • 11.6.1 Key Facts
  • 11.6.2 Business Description
  • 11.6.3 Products and Services
  • 11.6.4 Financial Overview
  • 11.6.5 SWOT Analysis
  • 11.6.6 Key Developments
• 11.7 Thermo Fisher Scientific Inc
  • 11.7.1 Key Facts
  • 11.7.2 Business Description
  • 11.7.3 Products and Services
  • 11.7.4 Financial Overview
  • 11.7.5 SWOT Analysis
  • 11.7.6 Key Developments
• 11.8 AGC Biologics AS
  • 11.8.1 Key Facts
  • 11.8.2 Business Description
  • 11.8.3 Products and Services
  • 11.8.4 Financial Overview
  • 11.8.5 SWOT Analysis
  • 11.8.6 Key Developments
• 11.9 Lonza Group AG
  • 11.9.1 Key Facts
  • 11.9.2 Business Description
  • 11.9.3 Products and Services
  • 11.9.4 Financial Overview
  • 11.9.5 SWOT Analysis
  • 11.9.6 Key Developments

12. Appendix

• 12.1 About The Insight Partners
• 12.2 Glossary of Terms